Evaluation and survey of malaria chemoprevention drug resistance in infant from Koutiala, Mali
Not Applicable
- Conditions
- Malaria
- Registration Number
- PACTR202401827533382
- Lead Sponsor
- AAS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
i. Child who received SP or AQ in the previous month;
ii. Child suffering from malaria diagnosed or under treatment at the time of implementation;
iii. Child with a known allergy to SP or AQ;
iv. adults never have taken SMC
Exclusion Criteria
1. Known allergy to SMC medicine
2. Child with severe malaria
3. Child on cotrimoxazole
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measuring molecular markers of SP+AQ resistance will provide evidence for the spread of drug-resistant parasites SMC implementation.
- Secondary Outcome Measures
Name Time Method In addition, measuring the incidence of malaria morbidity and mortality may correspond to a decline in SMC effectiveness over the past ten years.